Literature DB >> 85676

Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers.

S B Svenson, A A Lindberg.   

Abstract

A coupling method for covalent attachment of acid labile oligosaccharides isolated from S. typhimurium O-polysaccharide to macromolecular carriers is described. Arylamine groups were introduced into the terminal reducing end of oligosaccharides by reacting them with 2-(4-aminophenyl)-ethylamine. After subsequent conversion to the corresponding saccharide-phenylisothiocyanato derivatives saccharides were covalently linked to free epsilon-lysylamine groups of different carrier proteins. The resulting conjugates were highly immunogenic and elicited in rabbits both anti-harptenic and anti-carrier protein specific antibodies. Some of the advantages of this coupling procedure are: (i) it can be used with oligosaccharides containing highly acid or alkali labile structures and/or glycosidic linkages, (ii) it produces conjugates with high degrees of substitution at low saccharide/protein molar input ratios, (iii) it does not grossly affect the immunogenic specificities of the carrier protein, and (iv) it is suitable for preparation of highly substituted affinity columns, e.g., coupling to a polyacrylamide matrix.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85676     DOI: 10.1016/0022-1759(79)90025-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  22 in total

1.  Expedient syntheses of neoglycoproteins using phase transfer catalysis and reductive amination as key reactions.

Authors:  R Roy; F D Tropper; A Romanowska; M Letellier; L Cousineau; S J Meunier; J Boratyński
Journal:  Glycoconj J       Date:  1991-04       Impact factor: 2.916

2.  Anti-Salmonella lipopolysaccharide monoclonal antibodies: characterization of Salmonella BO-, CO-, DO-, and EO-specific clones and their diagnostic usefulness.

Authors:  J M Luk; A A Lindberg
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

3.  Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.

Authors:  G J Zigterman; K Schotanus; E B Ernste; G J Van Dam; M Jansze; H Snippe; J M Willers
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

4.  Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3.

Authors:  H Snippe; A J van Houte; J E van Dam; M J De Reuver; M Jansze; J M Willers
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

5.  Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice.

Authors:  S B Svenson; A A Lindberg
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

6.  Studies on the reductive amination of 3-deoxy-D-manno-octulosonic acid (Kdo).

Authors:  H D Grimmecke; H Brade
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

Review 7.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

8.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis.

Authors:  H J Jennings; C Lugowski; F E Ashton
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

10.  Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.

Authors:  J A Roberts; M B Kaack; G Baskin; S B Svenson
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.